Specifically, PD-1/PD-L1 expression was evaluated by the CRI-SU2C Dream Team, which revealed the association between PD-L1 expression and responses to PD-1/PD-L1 checkpoint immunotherapy in patients with various types of cancers [82]. The gene discussed is CD274; the disease is cancer.